{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:12:31Z","timestamp":1783696351464,"version":"3.55.0"},"reference-count":41,"publisher":"Becaris Publishing Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    To examine the characteristics, treatment patterns, and physicians' assessments of outcomes for patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or dermatomyositis\/polymyositis (DM\/PM) who received Acthar Gel.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    This survey-based medical chart review study asked rheumatologists who met specific inclusion criteria to abstract data from patient records covering the period from April 2022 to November 2024. Eligible patients were adults \u226518\u00a0years diagnosed with RA, SLE, or DM\/PM, treated with Acthar Gel for \u226424\u00a0months. An online questionnaire screened and identified contributing physicians and collected anonymized patient data (baseline demographic, medical history, concomitant medications, Acthar Gel treatment history, and physicians' assessment of health status, symptom severity, treatment outcomes with Acthar Gel).\n                    <jats:bold>Results:<\/jats:bold>\n                    The study population comprised 73 patients with RA (average age 50\u00a0years; 49 [67%] female; 44 [60%] White\/non-Hispanic), 56 with SLE (average age 42\u00a0years; 47 [84%] female; 28 [50%] African\u2013American), and 104 with DM\/PM (average age 52\u00a0years; 69 [66%] female; 62 [60%] White\/non-Hispanic). Patients had received Acthar Gel for an average of 9 (RA) or 8\u00a0months (SLE, DM\/PM), with most receiving treatment at the time of the study. Per physicians' assessment, health status improved in 68 (93%) patients with RA, 50 (89%) patients with SLE, and 100 (96%) patients with DM\/PM after starting treatment with Acthar Gel. The most common treatment goals achieved in patients with improved overall health status were improved overall symptoms, pain, physical function, and corticosteroid use in the RA cohort; overall symptoms, pain, corticosteroid use, and fatigue in the SLE cohort; and overall symptoms, strength, physical function, and corticosteroid use in the DM\/PM cohort.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    These findings support the use of Acthar Gel as a potential treatment option for appropriate patients with RA, SLE, or DM\/PM.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0200","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:59:37Z","timestamp":1782395977000},"source":"Crossref","is-referenced-by-count":0,"title":["Acthar Gel treatment in patients with rheumatoid arthritis, systemic lupus erythematosus, or dermatomyositis\/polymyositis: analysis of physician-reported charts"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-4738","authenticated-orcid":false,"given":"Kyle","family":"Hayes","sequence":"first","affiliation":[{"name":"Keenova Therapeutics, formerly Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Patel","sequence":"additional","affiliation":[{"name":"Indegene Inc., Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka P","family":"Shanbhag","sequence":"additional","affiliation":[{"name":"Indegene Inc., Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destri R","family":"Evans","sequence":"additional","affiliation":[{"name":"Indegene Inc., Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Prince","family":"Panaccio","sequence":"additional","affiliation":[{"name":"Keenova Therapeutics, formerly Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Purcell","sequence":"additional","affiliation":[{"name":"Keenova Therapeutics, formerly Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-740X","authenticated-orcid":false,"given":"George J","family":"Wan","sequence":"additional","affiliation":[{"name":"Keenova Therapeutics, formerly Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"10","key":"e_1_3_9_3_2","first-page":"3594","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"5","author":"GBD_Rheumatoid_Collaborators","year":"2023","unstructured":"GBD_Rheumatoid_Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 5(10), 3594\u20133610 (2023).","journal-title":"Lancet Rheumatol."},{"issue":"11","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3390\/cells10112857","article-title":"Management of rheumatoid arthritis: an overview","volume":"10","author":"Radu AF","year":"2021","unstructured":"Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells 10(11), 2857 (2021).","journal-title":"Cells"},{"issue":"1","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82(1), 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79(6), 85\u201399 (2020).","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.41632","article-title":"Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries","volume":"73","author":"Izmirly PM","year":"2021","unstructured":"Izmirly PM, Parton H, Wang L Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 73(6), 991\u2013996 (2021).","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"e_1_3_9_8_2","first-page":"383","article-title":"Systemic lupus erythematosus: diagnosis and treatment","volume":"107","author":"Lam NV","year":"2023","unstructured":"Lam NV, Brown JA, Sharma R. Systemic lupus erythematosus: diagnosis and treatment. Am. Fam. Physician 107(4), 383\u2013395 (2023).","journal-title":"Am. Fam. Physician"},{"key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-med-043021-032611","article-title":"Systemic lupus erythematosus: new diagnostic and therapeutic approaches","volume":"74","author":"Lazar S","year":"2023","unstructured":"Lazar S, Kahlenberg JM. Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annu. Rev. Med. 74, 339\u2013352 (2023).","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt J","year":"2018","unstructured":"Schmidt J. Current classification and management of inflammatory myopathies. J. Neuromuscul. Dis. 5(2), 109\u2013129 (2018).","journal-title":"J. Neuromuscul. Dis."},{"issue":"2","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/acr.24786","article-title":"Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study","volume":"75","author":"Kronzer VL","year":"2023","unstructured":"Kronzer VL, Kimbrough BA, Crowson CS, Davis JM 3rd, Holmqvist M, Ernste FC. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res. 75(2), 348\u2013355 (2023).","journal-title":"Arthritis Care Res."},{"key":"e_1_3_9_12_2","volume-title":"Prescribing information","author":"Acthar Gel (repository cortiotropin injection)","year":"2024","unstructured":"Acthar Gel (repository cortiotropin injection). Prescribing information. Mallinckrodt, NJ, USA (2024)."},{"key":"e_1_3_9_13_2","first-page":"21","article-title":"Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone","volume":"4","author":"Ross AP","year":"2013","unstructured":"Ross AP, Ben-Zacharia A, Harris C, Smrtka J. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front. Neurol. 4, 21 (2013).","journal-title":"Front. Neurol."},{"issue":"3","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.smim.2015.02.003","article-title":"ACTH: the forgotten therapy","volume":"27","author":"Montero-Melendez T","year":"2015","unstructured":"Montero-Melendez T. ACTH: the forgotten therapy. Semin. Immunol. 27(3), 216\u2013226 (2015).","journal-title":"Semin. Immunol."},{"issue":"1","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s41030-022-00181-0","article-title":"Repository corticotropin injection for the treatment of pulmonary sarcoidosis: a narrative review","volume":"8","author":"Mirsaeidi M","year":"2022","unstructured":"Mirsaeidi M, Baughman RP. Repository corticotropin injection for the treatment of pulmonary sarcoidosis: a narrative review. Pulm. Ther. 8(1), 43\u201355 (2022).","journal-title":"Pulm. Ther."},{"issue":"2","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40744-020-00199-3","article-title":"Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial","volume":"7","author":"Fleischmann R","year":"2020","unstructured":"Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial. Rheumatol. Ther. 7(2), 327\u2013344 (2020).","journal-title":"Rheumatol. Ther."},{"issue":"2","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40744-022-00429-w","article-title":"Post hoc analysis of predictors of clinical response to repository corticotropin injection in persistently active rheumatoid arthritis","volume":"9","author":"Fleischmann R","year":"2022","unstructured":"Fleischmann R, Hayes K, Ahn SW Post hoc analysis of predictors of clinical response to repository corticotropin injection in persistently active rheumatoid arthritis. Rheumatol. Ther. 9(2), 649\u2013661 (2022).","journal-title":"Rheumatol. Ther."},{"issue":"2","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40744-021-00412-x","article-title":"Post hoc analysis of the correlation between patient-reported outcomes and clinical response to repository corticotropin injection for persistently active rheumatoid arthritis","volume":"9","author":"Fleischmann R","year":"2022","unstructured":"Fleischmann R, Hayes K, Ahn SW Post hoc analysis of the correlation between patient-reported outcomes and clinical response to repository corticotropin injection for persistently active rheumatoid arthritis. Rheumatol. Ther. 9(2), 435\u2013446 (2022).","journal-title":"Rheumatol. Ther."},{"key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/OARRR.S131046","article-title":"Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action","volume":"9","author":"Gillis T","year":"2017","unstructured":"Gillis T, Crane M, Hinkle C, Wei N. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action. Open Access Rheumatol. 9, 131\u2013138 (2017).","journal-title":"Open Access Rheumatol."},{"key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/annrheumdis-2015-eular.2810","article-title":"The effect of corticotropin (ACTH 80 units weekly or biweekly) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective as measured by a CDAI score and osteitis, synovitis, and erosions on MRI","volume":"74","author":"Gaylis N","year":"2015","unstructured":"Gaylis N, Needell S, Sagliani J. The effect of corticotropin (ACTH 80 units weekly or biweekly) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective as measured by a CDAI score and osteitis, synovitis, and erosions on MRI. Ann. Rheum. Dis. 74, 1066 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0961203314532562","article-title":"Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial","volume":"23","author":"Fiechtner JJ","year":"2014","unstructured":"Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus 23(9), 905\u2013912 (2014).","journal-title":"Lupus"},{"issue":"1","key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40744-021-00294-z","article-title":"Patient-reported outcomes from a Phase 4, multicenter, randomized, double-blind, placebo-controlled trial of repository corticotropin injection (Acthar(\u00ae) Gel) for persistently active systemic lupus erythematosus","volume":"8","author":"Askanase AD","year":"2021","unstructured":"Askanase AD, Wan GJ, Panaccio MP Patient-reported outcomes from a Phase 4, multicenter, randomized, double-blind, placebo-controlled trial of repository corticotropin injection (Acthar(\u00ae) Gel) for persistently active systemic lupus erythematosus. Rheumatol. Ther. 8(1), 573\u2013584 (2021).","journal-title":"Rheumatol. Ther."},{"issue":"4","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40744-020-00236-1","article-title":"Repository corticotropin injection for persistently active systemic lupus erythematosus: results from a Phase 4, multicenter, randomized, double-blind, placebo-controlled trial","volume":"7","author":"Askanase AD","year":"2020","unstructured":"Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository corticotropin injection for persistently active systemic lupus erythematosus: results from a Phase 4, multicenter, randomized, double-blind, placebo-controlled trial. Rheumatol. Ther. 7(4), 893\u2013908 (2020).","journal-title":"Rheumatol. Ther."},{"issue":"4","key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s40744-021-00353-5","article-title":"Correction to: repository corticotropin injection for persistently active systemic lupus erythematosus: results from a Phase 4, multicenter, randomized, double-blind, placebo-controlled trial","volume":"8","author":"Askanase AD","year":"2021","unstructured":"Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Correction to: repository corticotropin injection for persistently active systemic lupus erythematosus: results from a Phase 4, multicenter, randomized, double-blind, placebo-controlled trial. Rheumatol. Ther. 8(4), 1915 (2021).","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"e000180","DOI":"10.1136\/lupus-2016-000180","article-title":"Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a Phase 4, randomised, controlled pilot study","volume":"3","author":"Furie R","year":"2016","unstructured":"Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a Phase 4, randomised, controlled pilot study. Lupus Sci. Med. 3(1), e000180 (2016).","journal-title":"Lupus Sci. Med."},{"issue":"1","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"e000240","DOI":"10.1136\/lupus-2017-000240","article-title":"Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study","volume":"4","author":"Furie RA","year":"2017","unstructured":"Furie RA, Mitrane M, Zhao E, Becker PM. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study. Lupus Sci. Med. 4(1), e000240 (2017).","journal-title":"Lupus Sci. Med."},{"key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.12688\/f1000research.7192.1","article-title":"Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: a retrospective study of patients","volume":"4","author":"Li X","year":"2015","unstructured":"Li X, Golubovsky J, Hui-Yuen J Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: a retrospective study of patients. F1000Res 4, 1103 (2015).","journal-title":"F1000Res"},{"key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/DDDT.S33110","article-title":"Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series","volume":"6","author":"Levine T","year":"2012","unstructured":"Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des. Devel. Ther. 6, 133\u2013139 (2012).","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4172\/2329-6895.1000292","article-title":"H.P. Acthar\u00ae Gel in Dermatomyositis and Polymyositis Treatment Registry: An Interim Analysis","volume":"4","author":"Levine T","year":"2016","unstructured":"Levine T, Malone J, Efthimiou P H.P. Acthar\u00ae Gel in Dermatomyositis and Polymyositis Treatment Registry: An Interim Analysis. J. Neurol. Disord. 4(5), 292 (2016).","journal-title":"J. Neurol. Disord."},{"issue":"8","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1097\/RHU.0000000000001422","article-title":"Efficacy of repository-corticotropin injection (Acthar) in refractory juvenile dermatomyositis: a case series","volume":"27","author":"Pender TM","year":"2021","unstructured":"Pender TM, Patel AM, Rosenkranz ME. Efficacy of repository-corticotropin injection (Acthar) in refractory juvenile dermatomyositis: a case series. J. Clin. Rheumatol. 27(Suppl. 8), S405 (2021).","journal-title":"J. Clin. Rheumatol."},{"issue":"12","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1093\/rheumatology\/kead595","article-title":"Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study","volume":"63","author":"Fernandez AP","year":"2024","unstructured":"Fernandez AP, Gallop J, Polly S, Khanna U. Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study. Rheumatology (Oxford, England) 63(12), 3370\u20133379 (2024).","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","article-title":"Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis","volume":"77","author":"Aggarwal R","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann. Rheum. Dis. 77(5), 720\u2013727 (2018).","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1093\/rheumatology\/keaa076","article-title":"Follow-up results of myositis patients treated with H. P. Acthar gel","volume":"59","author":"Saygin D","year":"2020","unstructured":"Saygin D, Oddis CV, Marder G Follow-up results of myositis patients treated with H. P. Acthar gel. Rheumatology (Oxford, England) 59(10), 2976\u20132981 (2020).","journal-title":"Rheumatology (Oxford, England)"},{"key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/CEOR.S130992","article-title":"Medical resource utilization in dermatomyositis\/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and\/or rituximab","volume":"9","author":"Knight T","year":"2017","unstructured":"Knight T, Bond TC, Popelar B Medical resource utilization in dermatomyositis\/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and\/or rituximab. Clinicoecon. Outcomes Res. 9, 271\u2013279 (2017).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"11","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1080\/13696998.2017.1362411","article-title":"Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis","volume":"20","author":"Wu B","year":"2017","unstructured":"Wu B, Deshpande G, Gu T, Popelar B, Philbin M, Wan GJ. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. J. Med. Econ. 20(11), 1170\u20131177 (2017).","journal-title":"J. Med. Econ."},{"issue":"2","key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40744-017-0087-x","article-title":"A retrospective medical record review of utilization patterns and medical resource use associated with repository corticotropin injection among patients with rheumatologic diseases in the United States","volume":"4","author":"Nelson WW","year":"2017","unstructured":"Nelson WW, Philbin MJ, Gallagher JR, Heap K, Carroll S, Wan GJ. A retrospective medical record review of utilization patterns and medical resource use associated with repository corticotropin injection among patients with rheumatologic diseases in the United States. Rheumatol. Ther. 4(2), 465\u2013474 (2017).","journal-title":"Rheumatol. Ther."},{"issue":"4","key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/8755122517709825","article-title":"Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: a claims data study","volume":"33","author":"Myung G","year":"2017","unstructured":"Myung G, Nelson WW, McMahon MA. Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: a claims data study. J. Pharm. Technol. 33(4), 151\u2013155 (2017).","journal-title":"J. Pharm. Technol."},{"key":"e_1_3_9_38_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/OARRR.S231667","article-title":"Treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis\/polymyositis","volume":"12","author":"Ho-Mahler N","year":"2020","unstructured":"Ho-Mahler N, Turner B, Eaddy M, Hanke ML, Nelson WW. Treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis\/polymyositis. Open Access Rheumatol. 12, 21\u201328 (2020).","journal-title":"Open Access Rheumatol."},{"key":"e_1_3_9_39_2","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1185\/03007995.2015.1062750","article-title":"Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study","volume":"31","author":"Shiozawa A","year":"2025","unstructured":"Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R. Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study. Curr. Med. Res. Opin. 31, 1611\u20131620 (2025).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_9_40_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/OARRR.S538839","article-title":"Treatment patterns and outcomes of Acthar Gel in ankylosing spondylitis and psoriatic arthritis: a physician-reported chart review","volume":"17","author":"Patel A","year":"2025","unstructured":"Patel A, Shanbhag PP, Evans DR, Hayes K, Panaccio MP, Wan GJ. Treatment patterns and outcomes of Acthar Gel in ankylosing spondylitis and psoriatic arthritis: a physician-reported chart review. Open Access Rheumatol. 17, 193\u2013202 (2025).","journal-title":"Open Access Rheumatol."},{"key":"e_1_3_9_41_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s41030-026-00344-3","article-title":"Symptomatic sarcoidosis treated with Acthar\u00ae Gel: insights from a physician-reported chart review","volume":"12","author":"Patel A","year":"2026","unstructured":"Patel A, Shanbhag P, Evans DR Symptomatic sarcoidosis treated with Acthar\u00ae Gel: insights from a physician-reported chart review. Pulm. Ther. 12, 385\u2013395 (2026).","journal-title":"Pulm. Ther."},{"key":"e_1_3_9_42_2","doi-asserted-by":"crossref","first-page":"2021-10-4","DOI":"10.7573\/dic.2021-10-4","article-title":"Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis","volume":"11","author":"Busch H","year":"2022","unstructured":"Busch H, Wan GJ, Niewoehner J Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis. Drug Context 11, 2021-10-4 (2022).","journal-title":"Drug Context"},{"key":"e_1_3_9_43_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/OARRR.S329766","article-title":"Real-world treatment patterns and outcomes from an electronic medical records database for patients with rheumatoid arthritis treated with repository corticotropin injection","volume":"15","author":"Hayes K","year":"2021","unstructured":"Hayes K, Panaccio MP, Houston P Real-world treatment patterns and outcomes from an electronic medical records database for patients with rheumatoid arthritis treated with repository corticotropin injection. Open Access Rheumatol. 15, 315\u2013323 (2021).","journal-title":"Open Access Rheumatol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:13:27Z","timestamp":1783692807000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.57264\/cer-2025-0200"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0200","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"e250200"}}